Association Between Enos Rs1799983 Polymorphism and Hypertension: a Meta-Analysis Involving 14,185 Cases and 13,407 Controls

Jikang Shi,Siyu Liu,Yanbo Guo,Sainan Liu,Jiayi Xu,Lingfeng Pan,Yueyang Hu,Yawen Liu,Yi Cheng
DOI: https://doi.org/10.1186/s12872-021-02192-2
IF: 2.174
2021-01-01
BMC Cardiovascular Disorders
Abstract:Background Essential hypertension is a complex disease determined by the interaction of genetic and environmental factors, eNOS is considered to be one of the susceptible genes for hypertension. Our study aimed to evaluate the association between eNOS rs1799983 polymorphism and hypertension, and to provide evidence for the etiology of hypertension. Methods Case–control studies of eNOS rs1799983 polymorphism and hypertension were included by searching PubMed, Embase, Web of Science, Medline, Scopus, WanFang datebase, Vip datebase, and CNKI database according to PRISMA guideline. Eligible data were extracted and pooled, and were analyzed using R software based on five different genetic models. Results A total of 60 eligible articles involving 14,185 cases and 13,407 controls were finally selected. We found significant association between eNOS rs1799983 polymorphism and hypertension under any genetic model (T vs G: OR = 1.44, 95% CI 1.26–1.63; GT vs GG: OR 1.34, 95% CI 1.18–1.52; TT vs GG: OR 1.80, 95% CI 1.41–2.31; GT + TT vs GG: OR 1.42, 95% CI 1.25–1.63; TT vs GG + GT: OR 1.68, 95% CI 1.35–2.08; GT vs GG + TT: OR 1.24, 95% CI 1.11–1.40). Conclusions We found that eNOS rs1799983 polymorphism is associated with the increased risk of hypertension under any genetic model. Moreover, investigations of gene–gene and gene-environment interactions are needed to give more insight into the association between eNOS rs1799983 polymorphism and hypertension.
What problem does this paper attempt to address?